SCHEMBL12342880

SCHEMBL12342880

CNc1ccc(-c2n[nH]c3ncc(-c4cccc(C(=O)N(C)C)c4)cc23)cc1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAP4K1 Q92918 3/20 0.57
▸ CYP3A4 P08684 2/20 0.57
▸ IGF1R P08069 6/20 0.48
▸ TNIK Q9UKE5 1/20 0.47
▸ FYN P06241 1/20 0.44
▸ NCOA1 Q15788 1/20 0.43
▸ NCOA3 Q9Y6Q9 1/20 0.43
▸ CDK1 P06493 1/20 0.42
▸ CDK2 P24941 1/20 0.42
▸ MKNK1 Q9BUB5 1/20 0.42
▸ MKNK2 Q9HBH9 1/20 0.42
▸ CDK8 P49336 1/20 0.41
▸ AXL P30530 1/20 0.41
▸ NEK1 Q96PY6 2/20 0.41
▸ ABL1 P00519 2/20 0.41
▸ ERN1 O75460 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12342977 0.90 CYP3A4 (0.62) MAP4K1CYP3A4IGF1RTNIKFYN
SCHEMBL12342879 0.90 CYP3A4 (0.55) MAP4K1CYP3A4IGF1RTNIK
SCHEMBL12342877 0.89 MAP4K1 (0.56) MAP4K1CYP3A4IGF1RTNIKFYN
SCHEMBL12342874 0.88 CYP3A4 (0.58) MAP4K1CYP3A4IGF1RTNIKFYN
SCHEMBL14042936 0.87 MAP4K1 (0.59) MAP4K1CYP3A4IGF1RTNIKFYN
SCHEMBL12342964 0.86 MAP4K1 (0.58) MAP4K1CYP3A4IGF1RTNIKNCOA1
SCHEMBL12342908 0.86 CYP3A4 (0.60) MAP4K1CYP3A4IGF1RTNIKFYN
SCHEMBL12342899 0.85 CYP3A4 (0.59) MAP4K1CYP3A4IGF1RTNIKFYN
SCHEMBL12342918 0.85 CYP3A4 (0.59) MAP4K1CYP3A4IGF1RTNIKFYN
SCHEMBL12342894 0.84 MAP4K1 (0.55) MAP4K1CYP3A4IGF1RTNIKCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8268994-B2 Fused ring heterocycle kinase modulators SGX PHARMACEUTICALS, INC. (US) 2012-09-18 — — US disclosed
US-8268994-B2 Fused ring heterocycle kinase modulators SGX PHARMACEUTICALS, INC. (US) 2012-09-18 — — US disclosed
US-20100036118-A1 Fused Ring Heterocycle Kinase Modulators SGX PHARMACEUTICALS, INC. 2010-02-11 — — US disclosed
US-20100036118-A1 Fused Ring Heterocycle Kinase Modulators SGX PHARMACEUTICALS, INC. 2010-02-11 — — US disclosed
US-7626021-B2 Fused ring heterocycle kinase modulators SGX PHARMACEUTICALS, INC. (US) 2009-12-01 — — US disclosed
US-7626021-B2 Fused ring heterocycle kinase modulators SGX PHARMACEUTICALS, INC. (US) 2009-12-01 — — US disclosed
WO-2008124850-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-16 — — WO disclosed
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-12-13 — — US disclosed
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-12-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS MAP3K20, TTK, MAP3K19 MAP4K1 19/4885CYP3A4 3559/4885IGF1R 798/4885
US-20100036118-A1 Fused Ring Heterocycle Kinase Modulators MAP3K20, TTK, MAP3K19 MAP4K1 19/4885CYP3A4 3559/4885IGF1R 798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback